research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
Stress-related hair loss was reversed with a special medication.
research Sequential high‐ and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata
High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research JAK UZYSKAĆ PRAWO PRACY JAKO LEKARZ W POLSCE, KWESTIA EGZAMINU JĘZYKOWEGO. PARADOKS POMIĘDZY BRAKAMI W ZAWODACH MEDYCZNYCH, A DOSTĘPEM DO ZAWODU LEKARZA W POLSCE DLA LEKARZY, KTÓRZY NIE STUDIOWALI W POLSCE
Recognize Polish academic titles as proof of language proficiency for foreign-trained doctors.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
Personalized treatments for hair loss focus on specific genetic and biological pathways.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research TĘTNIAK AORTY NA OSI CZASU – CZY, KIEDY I JAK LECZYĆ
Aortic aneurysm treatment has shifted to less invasive methods, improving safety and outcomes.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Topical Janus kinase inhibitors: A review of applications in dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research New small molecules in dermatology: for the autoimmunity, inflammation and beyond
New small molecule drugs show promise in treating complex skin diseases but need more safety research.
research Janus kinase inhibitors in dermatology: A systematic review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.